Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.
Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.
Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.
Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.
Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of
Amgen (NASDAQ: AMGN) will host a webcast call for investors on June 4, 2021, at 4:00 p.m. ET, during the ASCO Annual Meeting. Dr. David M. Reese and the clinical development team will discuss key clinical data on the FDA-approved KRAS inhibitor LUMAKRAS™ (sotorasib), plus anti-FGFR2b antibody bemarituzumab and the bispecific T-cell engager tarlatamab. The live audio will be accessible to media, investors, and the public via Amgen's website. The recording will remain available for 90 days post-event.
Amgen and Kyowa Kirin have announced a global collaboration to jointly develop KHK4083, a potential first-in-class treatment for moderate-to-severe atopic dermatitis. Amgen will lead the development and commercialization worldwide, except in Japan, where Kyowa Kirin retains rights. The agreement includes a $400 million upfront payment from Amgen and additional milestone payments up to $850 million. KHK4083 has shown promising Phase 2 results, significantly improving symptoms in patients. The partnership builds on a long history of collaboration, leveraging Amgen's expertise and Kyowa Kirin's innovative technology.
Amgen (NASDAQ: AMGN) will present at the 2021 Jefferies Healthcare Conference on June 3, 2021, at 1:30 p.m. ET. Murdo Gordon, executive vice president of Global Commercial Operations, will lead the presentation. The conference call will be streamed live online, accessible to media, investors, and the public. Interested individuals can access the webcast on Amgen's website, where it will also be archived for 90 days.
Amgen specializes in innovative therapeutics and aims to meet high unmet medical needs, enhancing health outcomes globally.
Amgen has received FDA approval for LUMAKRAS™ (sotorasib) to treat adults with KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have undergone at least one prior therapy. This accelerated approval is based on positive data showing a 36% overall response rate and a median duration of response of 10 months from the CodeBreaK 100 trial. The approval represents a significant advancement in targeted therapies for this mutation, which affects about 13% of non-squamous NSCLC patients in the U.S. Amgen is also providing companion diagnostics for effective biomarker testing.
Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 21, 2021, at 11:20 a.m. ET. Dr. David M. Reese, the executive vice president of Research and Development, will represent the company. The conference call will be streamed live, accessible to media, investors, and the public via Amgen's website. An archived version of the webcast will be available for at least 90 days post-event. Amgen is committed to discovering and delivering innovative therapies targeting high unmet medical needs, advancing human health since 1980.
Amgen will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 21, 2021, at 11:20 a.m. ET. The presentation will be led by David M. Reese, M.D., Executive Vice President of Research and Development. A live audio broadcast will be available for media, investors, and the public. The webcast can be accessed on Amgen's website and will be available for replay for 90 days. Amgen focuses on delivering innovative human therapeutics to address significant medical needs.
Amgen (NASDAQ: AMGN) announced the presentation of new oncology data at the 2021 ASCO Annual Meeting from June 4-8, 2021. Key highlights include the first-time presentation of overall survival data from the Phase 2 CodeBreaK 100 trial for LUMAKRAS™ (sotorasib) in non-small cell lung cancer (NSCLC). Additionally, updated results for bemarituzumab in advanced gastric cancer will be shared. Amgen’s webcast investor call is set for June 4, 2021, at 4:00 p.m. ET, where executives will discuss these pivotal findings.
Amgen and AstraZeneca reported significant results from the NAVIGATOR Phase 3 trial of tezepelumab, a potential treatment for severe asthma, showcasing superiority across primary and secondary endpoints versus placebo. Key findings include a 77% reduction in annualized asthma exacerbation rates and an 85% reduction in hospitalization rates for patients treated with tezepelumab. Results also indicated improvements in lung function and quality of life. Despite setbacks in the SOURCE Phase 3 trial, where the primary endpoint was not met, further analyses showed promising outcomes for patients on chronic oral corticosteroid therapy.
Amgen (NASDAQ:AMGN) announced the presentation of four cardiovascular research abstracts at the American College of Cardiology's 70th Annual Scientific Session & Expo (ACC.21), taking place May 15-17, 2021. Key highlights include final data from the Repatha® (evolocumab) trial for HIV patients with high cholesterol, confirming its safety and efficacy. The PROFICIO program, encompassing 50 trials and over 47,000 patients, supports the treatment's impact on cardiovascular disease. With over one million patients treated with Repatha globally, Amgen is committed to advancing cardiovascular treatment.
Amgen announced that AstraZeneca submitted a Biologics License Application (BLA) for tezepelumab to the FDA. This potential first-in-class treatment aims to address severe asthma, with clinical trials indicating a significant reduction in asthma exacerbations. The pivotal NAVIGATOR Phase 3 trial showed tezepelumab's ability to reduce exacerbation rates regardless of baseline eosinophil counts, making it unique among biologics. Tezepelumab targets thymic stromal lymphopoietin, key in asthma inflammation.
This submission is a step towards offering a transformative treatment for severe asthma patients.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
